GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridg
Financial Modeling Prep is a new concept that informs you about stock markets information (news, currencies and stock prices).
We always strive to give you the best and most updated information. We also gives you free financial modeling methodology
through our academy. Most investment banking firms follow our guidelines to get discounted cash flow statement of companies to
see if they are undervalued, overvalued or simply at par value. You can find all financial models and valuation techniques
that is used in corporate finance to get companies intrinsic valuation. Most private equity firm use financial modeling for
decision making when it comes to hold, buy or sell a particular stock.